LEO Pharma to Showcase Its Broadest Ever Scientific Program at EADV 2026 (Businesswire) - Sep 24, 2026 - "A key focus of the program is tralokinumab, with eight original abstracts accepted, including two oral presentations and six ePosters. New real-world TRACE data will highlight tralokinumab’s impact in patients with moderate-to-severe atopic dermatitis involving high-burden areas such as head & neck, hands, feet and genitals, alongside associated changes in quality of life...The program includes four spesolimab abstracts covering generalized pustular psoriasis and pyoderma gangrenosum, with data on long-term efficacy, flare management and unmet needs in diagnosis and treatment. LEO Pharma will also present new brodalumab data in plaque psoriasis, including comparative analyses in patients with overweight or obesity."
Clinical data • Atopic Dermatitis • Immunology • Obesity • Plaque Psoriasis • Psoriasis • Pustular Psoriasis
|